Table 4 Principal component analysis of serum biomarkers in ankylosing spondylitis patients at baseline
PC1 | PC2 | PC3 | PC4 | PC5 | PC6 | PC7 | PC8 |
|---|---|---|---|---|---|---|---|
IL-15 (0.972) | IFNγ (0.955) | MMP-8 (0.849) | GM-CSF (0.913) | CXCL10 (-0.676) | MMP-2 (-0.700) | bFGF (0.744) | EGF (0.735) |
IL-2 (0.970) | IL-12 (0.936) | MMP-9 (0.796) | IL-10 (0.813) | IL-13 (0.626) | MMP-3 (-0.759) | IL-1Ra (0.493) | CXCL8 (0.436) |
MIP-1β (0.930) | IL-5 (0.842) | CXCL8 (0.527) |  | VEGF (0.437) |  |  | MCP-1 (0.425) |
IFNα (0.916) | Eotaxin (0.760) | HGF (0.453) |  |  |  |  |  |
IL-1β (0.877) | IL-2R (0.712) |  |  |  |  |  |  |
TNFα (0.841) | IL-17 (0.633) |  |  |  |  |  |  |
MIP-1α (0.812) | IL-4 (-0.565) |  |  |  |  |  |  |
IL-7 (0.771) | IL-13 (0.525) | Â | Â | Â | Â | Â | Â |
IL-6 (0.736) | MCP-1 (0.499) | Â | Â | Â | Â | Â | Â |
MIG (0.722) | VEGF (-0.477) | Â | Â | Â | Â | Â | Â |
IL-1Ra (0.680) | TNFα (0.408) |  |  |  |  |  |  |
IL-17 (0.674) | Â | Â | Â | Â | Â | Â | Â |
IL-4 (0.673) | Â | Â | Â | Â | Â | Â | Â |
IL-2R (0.609) | Â | Â | Â | Â | Â | Â | Â |
GCSF (0.486) | Â | Â | Â | Â | Â | Â | Â |
HGF (0.462) | Â | Â | Â | Â | Â | Â | Â |
30.16%a | 17.61%a | 6.63%a | 6.03%a | 4.80%a | 3.90%a | 4.70%a | 4.44%a |